Emerald Health Therapeutics Expands Adult-Use Cannabis Distribution to Additional Provinces
May 14 2019 - 7:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has been authorized by PEI Cannabis and Manitoba Liquor
& Lotteries Corporation to supply Emerald-branded cannabis
products into those provinces. Emerald has also fulfilled its first
shipments of premium cannabis products to PEI Cannabis and to
licensed private retailers in Saskatchewan.
“We are pleased to have the opportunity to serve
additional provinces,” said Dr. Avtar Dhillon, President and
Executive Chairman of Emerald. “We believe that our growing
nationwide presence reflects the recognition of Emerald as a
reliable and consistent cannabis supplier. We look forward to
continuing to expand our supply of quality Emerald cannabis
products to the Canadian adult-use market.”
Emerald’s cannabis supply is provided by its
Verdélite indoor facility in Québec and Pure Sunfarms, its
50%-owned joint venture in British Columbia that is fully planted
in its 1.03 million square foot greenhouse growing area. Pure
Sunfarms is on track to reach its annualized production run-rate of
75,000 kg by mid-2019.
Emerald is currently delivering cannabis to the
Ontario Cannabis Retail Corporation, Cannabis Retail Store (CRS),
the British Columbia Liquor Distribution Board (BCLDB), the
Newfoundland Labrador Liquor Corporation, and the Yukon Liquor
Corporation. It has also signed a letter of intent with the Société
Québécoise du Cannabis (SQDC) to supply cannabis to Quebec and a
sales agreement with the Alberta Gaming, Liquor and Cannabis (AGLC)
to supply cannabis to Alberta.
About Emerald Health
Therapeutics
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is licensed and in full production in 1.03 million
square feet of the first of its two 1.1 million square foot
greenhouses. The capacity of each greenhouse is estimated to exceed
75,000 kg of cannabis annually. Emerald’s Verdélite operation in
Saint Eustache, Québec is completing the build-out of its 88,000
square foot indoor cultivation facility and is scaling up
production. Emerald has contracted for approximately 1000 acres of
hemp in 2019 to 2022, with the objective of extracting low-cost
cannabidiol. Emerald has secured exclusive strategic partnerships
for large scale extraction and softgel encapsulation, as well as
for proprietary technology to enhance cannabinoid bioavailability.
Its team is highly experienced in life sciences, product
development, large-scale agri-business, and marketing, and is
focused on developing proprietary, value-added cannabis products
for medical and adult-use customers.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products aimed at
providing wellness and medical benefits by interacting with the
human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or
contact: Rob Hill, Chief Financial Officer (800) 757 3536 Ext. #
5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024